CClinicalTrials.gg
CompletedNCT01847248Updated Nov 25, 2013

HSPA12B as a Potential Biomarker for Sepsis and Severe Sepsis

An observational study in Sepsis, sponsored by Changhai Hospital. Completed at 1 site in China. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2013-11-25.

Sponsored by Changhai Hospital · Observational

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
118
Ages
18 Years and older
Sex
All
01

Study summary

  • Molecules indicating endothelial injury may serve as biomarkers for severe sepsis because of the critical role of endothelial injury in organ dysfunction during severe sepsis.
  • HSPA12B is primarily located in endothelial cells and detectable during sepsis.
  • The investigators speculated that HSPA12B from endothelial cells might be correlated with severe sepsis.
02

Conditions studied

  • Sepsis

Browse trials for

Keywords

  • sepsis
  • biomarker
  • HSPA12B
03

In context

Sepsis

1,899 studies on the registry are indexed under Sepsis; 458 are open to participants now.

This study's enrollment of 118 is below the median of 160 across 929 observational studies indexed under Sepsis.

Browse Sepsis studies →

Lead sponsor

Changhai Hospital is the lead sponsor of 342 studies on the registry; 133 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Continuous patients with sepsis, severe sepsis, SIRS after major orthopedics surgery and healthy volunteers

Inclusion criteria

  • Adult patients
  • Patients meet the diagnostic criteria according to the grouping

Exclusion criteria

Exclusion Criteria:

  • patients without informed consent
  • patients who were undergoing continuous renal replacement therapy before sampling
  • patients with special infection induced by virus, tubercle bacillus, mycoplasma, Chlamydia, and so on
05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
118 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • sepsis

    Patients with sepsis but not severe sepsis

  • Severe sepsis

    Patients with severe sepsis

  • SIRS

    Patients with SIRS after major orthopedics surgery

  • Control

    Healthy volunteers

06

What researchers measure

Primary outcomes

  1. 28-day mortality

    mortality within 28 days after recruitment.

    Time frame: 28 days

07

Study locations

1 site
  • Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital
    Shanghai, 200433, China
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 25, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01847248
Lead sponsor
Changhai Hospital
Responsible party
Jia-feng Wang (Dr., Changhai Hospital) — Principal investigator
First posted
May 6, 2013
Start date
May 2011
Primary completion
Mar 2013
Completion
Oct 2013
Last update
Nov 25, 2013

Study contacts

Ke-ming Zhu, M.D.
principal investigator · Department of Anesthesiology and Intensive Care Medicine, Changhai Hospital

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion